DK2741085T3 - Fremgangsmåde til detektering af pancreascancer - Google Patents
Fremgangsmåde til detektering af pancreascancer Download PDFInfo
- Publication number
- DK2741085T3 DK2741085T3 DK12819473.5T DK12819473T DK2741085T3 DK 2741085 T3 DK2741085 T3 DK 2741085T3 DK 12819473 T DK12819473 T DK 12819473T DK 2741085 T3 DK2741085 T3 DK 2741085T3
- Authority
- DK
- Denmark
- Prior art keywords
- gin
- ser
- glu
- pro
- ala
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (14)
1. Fremgangsmåde til detektering af pancreascancer, omfattende at måle, i en prøve adskilt fra et individ: (i) tilstedeværelse eller en mængde af et polypeptid med en reaktivitet med specifik binding til et antistof mod et CAPRIN-1-protein via en antigen-antistof-reaktion eller (ii) et antistof mod CAPRIN-1-protein eller (iii) tilstedeværelse eller en mængde af en nukleinsyre, der koder for CAPRIN-1-protein, hvor CAPRIN-1-proteinet består af en aminosyresekvens repræsenteret af et hvilket som helst af SEQ ID Nos: 2 til 30 med lige nummer.
2. Fremgangsmåde ifølge krav 1, hvor polypeptidet er et CAPRIN-1-protein bestående af en aminosyresekvens repræsenteret af et hvilket som helst af SEQ ID NOs: 2 til 30 med lige nummer, eller et polypeptid bestående af en aminosyresekvens med 85-90 % sekvensidentitet eller højere med CAPRIN-1-proteinet.
3. Fremgangsmåde ifølge krav 1 eller 2, hvor individet er et menneske eller en hund.
4. Fremgangsmåde ifølge krav 3, hvor individet er en hund, og CAPRIN-1-proteinet omfatter aminosyresekvensen repræsenteret af SEQ ID NO: 6, 8, 10, 12 eller 14.
5. Fremgangsmåde ifølge krav 3, hvor individet er et menneske, og CAPRIN-1-proteinet omfatter aminosyresekvensen repræsenteret af SEQ ID NO: 2 eller 4.
6. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 5, hvor tilstedeværelsen eller mængden af nukleinsyren i prøven måles under anvendelse af et polynukleotid, der specifikt hybridiserer til en delsekvens omfattende 15-19 eller flere nukleotider eller 20-30 eller flere nukleotider i nukleotidsekvensen af nukleinsyren eller en sekvens, der er komplementær dertil.
7. Fremgangsmåde ifølge krav 6, hvor individet er en hund, og polynukleoti-det specifikt hybridiserer til en delsekvens omfattende 15-19 eller flere nu-kleotider eller 20-30 eller flere nukleotider i nukleotidsekvensen repræsenteret af SEQ ID NO: 5, 7, 9, 11 eller 13 eller en sekvens, der er komplementær dertil.
8. Fremgangsmåde ifølge krav 6, hvor individet er et menneske, og polynu-kleotidet specifikt hybridiserer til en delsekvens omfattende 15-19 eller flere nukleotider eller 20-30 eller flere nukleotider i nukleotidsekvensen repræsenteret af SEQ ID NO: 1 eller 3 eller en sekvens, der er komplementær dertil.
9. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 5, hvor tilstedeværelsen eller mængden af polypeptidet bestemmes ved at måle polypepti-det indeholdt i prøven i et immunologisk assay.
10. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 9, hvor prøven er blod, serum, blodplasma, ascitesvæske, pleuraekssudat, væv eller celler.
11. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 10, hvor antistoffet, der gennemgår en antigen-antistof-reaktion med polypeptidet, er et antistof, der binder til overfladen af en pancreascancercelle.
12. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 11, hvor det antistof, der gennemgår en antigen-antistof-reaktion med polypeptidet, omfatter et antistof med en immunologisk reaktivitet med et polypeptid bestående af en aminosyresekvens omfattende mindst 7 til 12 fortløbende aminosyrere-ster inden for regionen af aminosyrerest Nos. 50 til 98 eller aminosyrerest Nos. 233 til 344 af aminosyresekvensen repræsenteret af et hvilket som helst af SEQ IDS NO: 2 til 30 med lige nummer, bortset fra SEQ ID NOs: 6 og 18.
13. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 12, hvor antistoffet, der gennemgår en antigen-antistof-reaktion med polypeptidet, er et eller flere antistoffer udvalgt fra gruppen bestående af: et antistof, der binder til et polypeptid omfattende aminosyresekvensen repræsenteret af SEQ ID NO: 43; et monoklonalt antistof omfattende aminosyresekvenserne repræsenteret af SEQ ID NOs: 44 og 45; et monoklonalt antistof omfattende ami- nosyresekvenserne repræsenteret af SEQ ID NOs: 44 og 46; et monoklonalt antistof omfattende aminosyresekvenserne repræsenteret af SEQ ID NOs: 44 og 47; et monoklonalt antistof omfattende aminosyresekvenserne repræsenteret af SEQ ID NOs: 44 og 48; et monoklonalt antistof omfattende aminosyresekvenserne repræsenteret af SEQ ID NOs: 49 og 50; et monoklonalt antistof omfattende aminosyresekvenserne repræsenteret af SEQ ID NOs: 51 og 52; et monoklonalt antistof omfattende aminosyresekvenserne repræsenteret af SEQ ID NOs: 53 og 54; et monoklonalt antistof omfattende aminosyresekvenserne repræsenteret af SEQ ID NOs: 55 og 56; et monoklonalt antistof omfattende aminosyresekvensen repræsenteret af SEQ ID NOs: 57 og 58; og et monoklonalt antistof omfattende aminosyresekvenserne repræsenteret af SEQ ID NOs: 59 og 60.
14. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 10, som anvender et reagens eller kit omfattende et eller flere polynukleotider, der specifikt hybridiserer til en delsekvens omfattende 15 til 19 eller flere nukleotider eller 20 til 30 eller flere nukleotider i nukleotidsekvensen repræsenteret af SEQ ID NOs: 1 til 29 med ulige nummer, og som koder for et CAPRIN-1-protein eller i en sekvens, der er komplementær til nukleotidsekvensen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011171364 | 2011-08-04 | ||
| PCT/JP2012/069824 WO2013018885A1 (ja) | 2011-08-04 | 2012-08-03 | 膵臓癌の検出方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2741085T3 true DK2741085T3 (da) | 2017-06-19 |
Family
ID=47629399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12819473.5T DK2741085T3 (da) | 2011-08-04 | 2012-08-03 | Fremgangsmåde til detektering af pancreascancer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9796775B2 (da) |
| EP (1) | EP2741085B1 (da) |
| JP (1) | JP6094220B2 (da) |
| KR (1) | KR101984554B1 (da) |
| CN (1) | CN103718045B (da) |
| AU (1) | AU2012290948B2 (da) |
| BR (1) | BR112014002616B1 (da) |
| CA (1) | CA2844033C (da) |
| DK (1) | DK2741085T3 (da) |
| ES (1) | ES2629061T3 (da) |
| HU (1) | HUE033628T2 (da) |
| MX (1) | MX349907B (da) |
| PL (1) | PL2741085T3 (da) |
| PT (1) | PT2741085T (da) |
| RU (1) | RU2624040C2 (da) |
| WO (1) | WO2013018885A1 (da) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2733492T3 (da) | 2008-08-05 | 2016-04-25 | Toray Industries | Fremgangsmåde til detektering af cancer |
| RU2498819C2 (ru) * | 2008-08-05 | 2013-11-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и профилактики злокачественных опухолей |
| RU2624029C2 (ru) | 2010-02-04 | 2017-06-30 | Торэй Индастриз, Инк. | Лекарственный препарат для лечения и/или профилактики рака |
| HUE030742T2 (en) | 2010-02-04 | 2017-06-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of cancer |
| DK2532364T3 (da) | 2010-02-04 | 2016-08-15 | Toray Industries | Farmaceutisk sammensætning omfattende anti caprin-1-antistoffer til behandling og/eller forebyggelse af kræft |
| RU2567657C2 (ru) | 2010-02-04 | 2015-11-10 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| BR112012018949A2 (pt) | 2010-02-04 | 2020-09-01 | Toray Industries | Composições farmacêuticas, anticorpos, combinação farmacêutica, métodos para o tratamento e/ou prevenção de um câncer, usos de uma composição farmacêutica, uso5 de um anticorpo e uso de uma combinação farmacêutica |
| DK2532365T3 (da) | 2010-02-04 | 2016-08-15 | Toray Industries | Farmaceutisk sammensætning til behandling og/eller forebyggelse af kræft |
| ES2618026T3 (es) | 2011-08-04 | 2017-06-20 | Toray Industries, Inc. | Composición farmacológica para el tratamiento y/o la prevención del cáncer |
| DK2740794T3 (da) | 2011-08-04 | 2018-06-14 | Toray Industries | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer |
| ES2609846T3 (es) | 2011-08-04 | 2017-04-24 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o prevención del cáncer pancreático |
| PT2740793T (pt) | 2011-08-04 | 2018-02-23 | Toray Industries | Composição de fármacos para o tratamento e/ou a prevenção de cancro |
| KR101980554B1 (ko) | 2011-08-04 | 2019-05-21 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| BR112014002616B1 (pt) | 2011-08-04 | 2022-01-18 | Toray Industries, Inc | Método para detectar câncer pancreático |
| ES2634249T3 (es) | 2011-08-04 | 2017-09-27 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer |
| MX357505B (es) | 2012-02-21 | 2018-07-12 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| BR112014021103A2 (pt) | 2012-02-21 | 2019-10-15 | Toray Industries, Inc | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo |
| EP2818482B1 (en) | 2012-02-21 | 2019-05-22 | Toray Industries, Inc. | Pharmaceutical composition for treatment of cancer |
| MX363136B (es) | 2012-02-21 | 2019-03-12 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| PL2832366T3 (pl) | 2012-03-30 | 2018-04-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego |
| CA2869120C (en) * | 2012-03-30 | 2023-05-23 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
| PT2876447T (pt) | 2012-07-19 | 2020-02-03 | Toray Industries | Método para deteção de cancro |
| JP6244911B2 (ja) | 2012-07-19 | 2017-12-13 | 東レ株式会社 | 癌の検出方法 |
| RU2678138C2 (ru) | 2013-08-09 | 2019-01-23 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| RU2612082C1 (ru) * | 2015-10-14 | 2017-03-02 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ прогнозирования направленности патологического процесса при раке головки поджелудочной железы |
| CN115317603A (zh) | 2016-07-07 | 2022-11-11 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| CN113993549A (zh) | 2019-03-15 | 2022-01-28 | 博尔特生物治疗药物有限公司 | 靶向her2的免疫缀合物 |
| RU2712921C1 (ru) * | 2019-08-12 | 2020-02-03 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ индивидуального прогнозирования сроков прогрессирования плоскоклеточного рака пищевода II-III стадии после хирургического лечения |
| JPWO2022138460A1 (da) * | 2020-12-24 | 2022-06-30 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100472213C (zh) | 1994-09-19 | 2009-03-25 | 里卡尔多·J·莫罗 | 癌症的检测和治疗 |
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
| IL140845A0 (en) | 1998-07-14 | 2002-02-10 | Corixa Corp | Compositions for therapy and diagnosis of prostate cancer |
| GB9815909D0 (en) | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
| US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6335170B1 (en) | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
| AU4185100A (en) | 1999-04-02 | 2000-10-23 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| CA2388822A1 (en) | 1999-10-29 | 2001-05-10 | Human Genome Sciences, Inc. | 27 human secreted proteins |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| CZ20023567A3 (cs) | 2000-03-29 | 2003-11-12 | Corixa Corporation | Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
| US20040236091A1 (en) | 2001-03-28 | 2004-11-25 | Chicz Roman M. | Translational profiling |
| WO2002083070A2 (en) | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| WO2002092001A2 (en) | 2001-05-11 | 2002-11-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
| JP2004535202A (ja) | 2001-07-17 | 2004-11-25 | リサーチ ディベロップメント ファンデーション | アポトーシス促進性蛋白質を含む治療剤 |
| RU2319709C2 (ru) | 2001-07-17 | 2008-03-20 | Рисерч Дивелопмент Фаундейшн | Терапевтические агенты, содержащие проапоптозные белки |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| EP2388265A1 (en) | 2002-02-22 | 2011-11-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| WO2004047728A2 (en) | 2002-11-26 | 2004-06-10 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
| EP1629119A2 (en) | 2003-04-29 | 2006-03-01 | Wyeth | Methods for diagnosing aml and mds by differential gene expression |
| US20050009067A1 (en) | 2003-05-19 | 2005-01-13 | Craig Logsdon | Expression profile of pancreatic cancer |
| JP2007516693A (ja) | 2003-06-09 | 2007-06-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | 癌の治療および診断のための組成物および方法 |
| WO2005007830A2 (en) | 2003-07-14 | 2005-01-27 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
| EP2361929A1 (en) | 2004-01-26 | 2011-08-31 | Debiovision Inc. | Neoplasm-specific polypeptides and their use |
| WO2005090407A1 (en) | 2004-03-19 | 2005-09-29 | Imclone Systems Incorporated | Human anti-epidermal growth factor receptor antibody |
| WO2005100998A2 (en) * | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
| WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
| SI1839662T1 (sl) | 2005-01-19 | 2010-07-30 | Zeria Pharm Co Ltd | Antitumorsko sredstvo |
| WO2006078307A1 (en) | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
| AU2006214105A1 (en) | 2005-02-18 | 2006-08-24 | Children's Medical Center Corporation | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
| US7510842B2 (en) | 2005-03-11 | 2009-03-31 | Vermilllion, Inc. | Biomarker for ovarian and endometrial cancer: hepcidin |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| CA2635616A1 (en) * | 2006-01-05 | 2007-07-19 | Carlo M. Croce | Microrna expression abnormalities in pancreatic endocrine and acinar tumors |
| EP1991701A4 (en) | 2006-02-14 | 2010-03-17 | Dana Farber Cancer Inst Inc | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFYING, EVALUATING, PREVENTING, AND TREATING CANCER |
| US20100015724A1 (en) | 2006-08-17 | 2010-01-21 | Peter Hornbeck | Lysine acetylation sites |
| US20080107668A1 (en) * | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7615349B2 (en) | 2006-09-07 | 2009-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
| WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
| CN106053833B (zh) | 2007-10-25 | 2018-12-25 | 东丽株式会社 | 癌的检测方法 |
| JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
| AR070865A1 (es) | 2008-03-18 | 2010-05-12 | Genentech Inc | Combinaciones de un conjugado anticuerpo- farmaco anti- her2 y agentes quimioterapeuticos y los metodos de uso |
| DK2733492T3 (da) | 2008-08-05 | 2016-04-25 | Toray Industries | Fremgangsmåde til detektering af cancer |
| KR101669827B1 (ko) | 2008-08-05 | 2016-10-27 | 도레이 카부시키가이샤 | 면역 유도제 |
| RU2498819C2 (ru) | 2008-08-05 | 2013-11-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и профилактики злокачественных опухолей |
| EA032728B1 (ru) | 2009-08-19 | 2019-07-31 | Мерк Патент Гмбх | Антитела для выявления комплексов интегрина в ffpe материале |
| MX2012003404A (es) | 2009-09-22 | 2012-09-12 | Volker Sandig | Procedimiento para producir moleculas que contienen estructuras de glicano especializadas. |
| RU2624029C2 (ru) | 2010-02-04 | 2017-06-30 | Торэй Индастриз, Инк. | Лекарственный препарат для лечения и/или профилактики рака |
| HUE030742T2 (en) | 2010-02-04 | 2017-06-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of cancer |
| DK2532364T3 (da) | 2010-02-04 | 2016-08-15 | Toray Industries | Farmaceutisk sammensætning omfattende anti caprin-1-antistoffer til behandling og/eller forebyggelse af kræft |
| DK2532365T3 (da) | 2010-02-04 | 2016-08-15 | Toray Industries | Farmaceutisk sammensætning til behandling og/eller forebyggelse af kræft |
| BR112012018949A2 (pt) | 2010-02-04 | 2020-09-01 | Toray Industries | Composições farmacêuticas, anticorpos, combinação farmacêutica, métodos para o tratamento e/ou prevenção de um câncer, usos de uma composição farmacêutica, uso5 de um anticorpo e uso de uma combinação farmacêutica |
| RU2567657C2 (ru) | 2010-02-04 | 2015-11-10 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| WO2012005550A2 (ko) | 2010-07-08 | 2012-01-12 | 강원대학교산학협력단 | 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 |
| KR101576174B1 (ko) | 2010-07-26 | 2015-12-09 | 르 라보레또레 쎄르비에르 | 간암 요법을 위한 방법 및 조성물 |
| KR101980554B1 (ko) * | 2011-08-04 | 2019-05-21 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| DK2740794T3 (da) * | 2011-08-04 | 2018-06-14 | Toray Industries | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer |
| ES2618026T3 (es) * | 2011-08-04 | 2017-06-20 | Toray Industries, Inc. | Composición farmacológica para el tratamiento y/o la prevención del cáncer |
| BR112014002616B1 (pt) | 2011-08-04 | 2022-01-18 | Toray Industries, Inc | Método para detectar câncer pancreático |
| ES2634249T3 (es) | 2011-08-04 | 2017-09-27 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer |
| ES2609846T3 (es) | 2011-08-04 | 2017-04-24 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o prevención del cáncer pancreático |
| PT2740793T (pt) * | 2011-08-04 | 2018-02-23 | Toray Industries | Composição de fármacos para o tratamento e/ou a prevenção de cancro |
| MX363136B (es) * | 2012-02-21 | 2019-03-12 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| EP2818482B1 (en) * | 2012-02-21 | 2019-05-22 | Toray Industries, Inc. | Pharmaceutical composition for treatment of cancer |
| MX357505B (es) * | 2012-02-21 | 2018-07-12 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| BR112014021103A2 (pt) * | 2012-02-21 | 2019-10-15 | Toray Industries, Inc | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo |
| PL2832366T3 (pl) | 2012-03-30 | 2018-04-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego |
| CA2869120C (en) | 2012-03-30 | 2023-05-23 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
| RU2678138C2 (ru) | 2013-08-09 | 2019-01-23 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
-
2012
- 2012-08-03 BR BR112014002616-5A patent/BR112014002616B1/pt active IP Right Grant
- 2012-08-03 CA CA2844033A patent/CA2844033C/en active Active
- 2012-08-03 JP JP2012543815A patent/JP6094220B2/ja active Active
- 2012-08-03 HU HUE12819473A patent/HUE033628T2/en unknown
- 2012-08-03 EP EP12819473.5A patent/EP2741085B1/en active Active
- 2012-08-03 US US14/236,807 patent/US9796775B2/en active Active
- 2012-08-03 ES ES12819473.5T patent/ES2629061T3/es active Active
- 2012-08-03 DK DK12819473.5T patent/DK2741085T3/da active
- 2012-08-03 WO PCT/JP2012/069824 patent/WO2013018885A1/ja active Application Filing
- 2012-08-03 PT PT128194735T patent/PT2741085T/pt unknown
- 2012-08-03 MX MX2014001377A patent/MX349907B/es active IP Right Grant
- 2012-08-03 CN CN201280038482.9A patent/CN103718045B/zh active Active
- 2012-08-03 PL PL12819473T patent/PL2741085T3/pl unknown
- 2012-08-03 AU AU2012290948A patent/AU2012290948B2/en active Active
- 2012-08-03 KR KR1020147005905A patent/KR101984554B1/ko active IP Right Grant
- 2012-08-03 RU RU2014108048A patent/RU2624040C2/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014002616B1 (pt) | 2022-01-18 |
| PL2741085T3 (pl) | 2017-09-29 |
| AU2012290948B2 (en) | 2017-05-25 |
| CA2844033C (en) | 2021-07-27 |
| EP2741085B1 (en) | 2017-04-05 |
| MX349907B (es) | 2017-08-18 |
| MX2014001377A (es) | 2014-03-21 |
| BR112014002616A2 (pt) | 2019-03-19 |
| HUE033628T2 (en) | 2017-12-28 |
| US20140179558A1 (en) | 2014-06-26 |
| EP2741085A1 (en) | 2014-06-11 |
| JPWO2013018885A1 (ja) | 2015-03-05 |
| CN103718045B (zh) | 2016-08-17 |
| RU2624040C2 (ru) | 2017-06-30 |
| RU2014108048A (ru) | 2015-09-10 |
| WO2013018885A1 (ja) | 2013-02-07 |
| PT2741085T (pt) | 2017-06-30 |
| ES2629061T3 (es) | 2017-08-07 |
| AU2012290948A1 (en) | 2014-03-20 |
| EP2741085A4 (en) | 2015-03-04 |
| JP6094220B2 (ja) | 2017-03-15 |
| CA2844033A1 (en) | 2013-02-07 |
| KR20140048318A (ko) | 2014-04-23 |
| CN103718045A (zh) | 2014-04-09 |
| US9796775B2 (en) | 2017-10-24 |
| KR101984554B1 (ko) | 2019-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2741085T3 (da) | Fremgangsmåde til detektering af pancreascancer | |
| DK2733492T3 (da) | Fremgangsmåde til detektering af cancer | |
| CA2879304C (en) | Method for detecting cancer | |
| KR102056137B1 (ko) | 암의 검출 방법 | |
| AU2017213844A1 (en) | Anti-ROR1 antibodies and uses thereof | |
| KR102429562B1 (ko) | 간세포암 진단용 바이오마커 세레브론 및 이에 특이적인 신규한 단일클론항체 | |
| JP6729917B2 (ja) | ＥｐｈＡ２ Ｎ末端フラグメント抗体 |